Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Minority Interest (2020 - 2025)

ImmunityBio (IBRX) has disclosed Minority Interest for 6 consecutive years, with $895000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Minority Interest fell 7.64% to $895000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $895000.0, a 7.64% decrease, with the full-year FY2025 number at $895000.0, down 7.64% from a year prior.
  • Minority Interest was $895000.0 for Q4 2025 at ImmunityBio, down from $909000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $1.1 million in Q3 2023 to a low of -$3.1 million in Q2 2023.
  • A 5-year average of -$416450.0 and a median of $673000.0 in 2021 define the central range for Minority Interest.
  • Peak YoY movement for Minority Interest: tumbled 523.95% in 2022, then soared 145.0% in 2023.
  • ImmunityBio's Minority Interest stood at -$1.7 million in 2021, then plummeted by 43.28% to -$2.5 million in 2022, then soared by 142.12% to $1.0 million in 2023, then dropped by 7.71% to $969000.0 in 2024, then dropped by 7.64% to $895000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Minority Interest are $895000.0 (Q4 2025), $909000.0 (Q3 2025), and $930000.0 (Q2 2025).